Giovanna Bossi is Principal Scientist at Immunocore. She has over 15 years’ experience in research and development, gained at Immunocore Ltd, UK. Giovanna leads Cell Biology research and preclinical activities aiming to develop TCR-based therapeutics for treatment of autoimmune diseases such as T1 diabetes. Giovanna joined the Autoimmune group in 2017 after spending previous 9 years in Oncology where she contributed to understand mechanism of action of the first in human ImmTAC (tabentafusp) for treatment of cutaneous melanoma and uveal melanoma. Tebentafusp demonstrated prolonged overall survival (OS) compared to investigator’s choice therapy in metastatic uveal melanoma patients in a Phase III trial. Tebentafusp is the first T cell receptor (TCR) therapeutic to demonstrate a survival benefit.
Following the completion of her DPhil from the Cellular Immunology Unit at the University of Pavia (Italy), a serial of Post Doctoral Research associated positions at Cancer Instititute IFOM-IEO in Milan and at the Sir William Dunn School of Pathology at University of Oxford, she joined Immunocore Ltd in 2006. Her area expertise span from cancer biology to cytotoxic T cells, cancer immunotherapy and autoimmune immunotherapy on which she has presented at International meetings and has contributed to various publications.